GPT and Hyperbilirubinemia: Among patients with HBV/HCV co-infection who achieved SVR, 2/52 patients suffered HBV flare up and received Nucs therapy during DAA treatment at week 9 and 8, with maximum ALT levels of 1584 U/L and 945 U/L without hyperbilirubinemia, respectively.